| Methods |
Randomisation: no information; Blinding:none;
Intention to treat: no;
Exclusion from analysis: 8/110;
Beginning of prophylaxis: chemotherapy;
End of prophylaxis: PMN count of 500 or development of side effects |
| Participants |
Hong Kong, single centre; 110 patients with haematological malignancies undergoing cytotoxic chemotherapy; Inpatients, university hospital |
| Interventions |
Ofloxacin 300mgX2/d versus trimethoprim‐sulphamethoxazole 80mg/400mgX2/d |
| Outcomes |
Infection related death; Febrile patients; Microbiologically documented febrile episodes;
Infection resistant to quinolones;
Adverse events |
| Notes |
Journal Publication |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
No details provided |
| Allocation concealment (selection bias) |
Unclear risk |
No details provided (B ‐ Unclear) |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Not blind |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
8/110 exclusions |
| Selective reporting (reporting bias) |
Unclear risk |
Analysis not by ITT |
